MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Ritonavir

CAS No. : 155213-67-5

MCE 国际站：Ritonavir

产品活性：Ritonavir (ABT 538) 是用于研究 HIV 感染和 AIDS 的 HIV 蛋白酶的抑制剂。Ritonavir 也是 SARS-CoV 3CL^pro 的抑制剂，IC₅₀ 为 1.61 μM。

研究领域：Anti-infection  |  Metabolic Enzyme/Protease  |  Apoptosis

作用靶点：HIV Protease  |  HIV  |  SARS-CoV  |  Apoptosis

In Vitro: Ritonavir (ABT 538) is an inhibitor of CYP3A4 mediated testosterone 6β-hydroxylation with mean K_i of 19 nM and also inhibits tolbutamide hydroxylation with IC₅₀ of 4.2 μM.
Ritonavir (ABT 538) is found to be a potent inhibitor of CYP3A-mediated biotransformations (nifedipine oxidation with IC₅₀ of 0.07 mM, 17alpha-ethynylestradiol 2-hydroxylation with IC₅₀ of 2 mM; terfenadine hydroxylation with IC₅₀ of 0.14 mM). Ritonavir is also an inhibitor of the reactions mediated by CYP2D6 (IC₅₀=2.5 mM) and CYP2C9/10 (IC₅₀=8.0 mM).
Ritonavir results in an increase in cell viability in uninfected human PBMC cultures. Ritonavir markedly decreases the susceptibility of PBMCs to apoptosis correlated with lower levels of caspase-1 expression, decreases in annexin V staining, and reduces caspase-3 activity in uninfected human PBMC cultures. Ritonavir inhibits induction of tumor necrosis factor (TNF) production by PBMCs and monocytes in a time- and dose-dependent manner at nontoxic concentrations.
Ritonavir inhibits p-glycoprotein-mediated extrusion of saquinavir with an IC₅₀ of 0.2 μM, indicating a high affinity of ritonavir for p-glycoprotein.
Ritonavir inhibits human liver microsomal metabolism of ABT-378 potently with K_i of 13 nM. Ritonavir combined with ABT-378 (at 3:1 and 29:1 ratios) inhibits CYP3A (IC₅₀=1.1 and 4.6 μM), albeit less potently than Ritonavir (IC₅₀=0.14 μM).

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Apoptosis Compound Library  |  Metabolism/Protease Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Antiviral Compound Library  |  CNS-Penetrant Compound Library  |  Peptidomimetic Library  |  Drug Repurposing Compound Library  |  Anti-COVID-19 Compound Library  |  NMPA-Approved Drug Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Rare Diseases Drug Library  |  Children’s Drug Library  |  EMA-Approved Drug Library  |  FDA-Approved Anticancer Drug Library  |  Human Metabolite Library  |  Heterocyclic Compound Library  |  Off-patent Drug Library  |  Protease Inhibitor Library   |  Cell Death Library  |  Multi-Target Compound Library  |  Bioactive Compound Library Max  |  MG-132  |  Chloroquine  |  Doxorubicin hydrochloride  |  Bafilomycin A1  |  Tamoxifen  |  Y-27632  |  Paclitaxel  |  Dexamethasone  |  Z-VAD-FMK  |  LY294002  |  2-Deoxy-D-glucose  |  Angiotensin II human  |  Acetylcysteine  |  Staurosporine  |  Actinomycin D  |  SB-431542  |  5-Fluorouracil  |  Bortezomib  |  Oxaliplatin  |  Deferoxamine mesylate  |  Sorafenib  |  Trametinib  |  Gemcitabine  |  Temozolomide  |  Etoposide  |  Rotenone  |  Mdivi-1  |  Monomethyl auristatin E  |  Decitabine  |  Ruxolitinib

热门产品线：重组蛋白  |  药物筛选  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。